BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 15194006)

  • 1. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
    Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
    Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
    Kusunoki N; Yamazaki R; Kawai S
    Arthritis Rheum; 2002 Dec; 46(12):3159-67. PubMed ID: 12483719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
    Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
    Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
    FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
    Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
    Maier TJ; Schilling K; Schmidt R; Geisslinger G; Grösch S
    Biochem Pharmacol; 2004 Apr; 67(8):1469-78. PubMed ID: 15041464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.
    Waskewich C; Blumenthal RD; Li H; Stein R; Goldenberg DM; Burton J
    Cancer Res; 2002 Apr; 62(7):2029-33. PubMed ID: 11929821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
    Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
    Leahy KM; Ornberg RL; Wang Y; Zweifel BS; Koki AT; Masferrer JL
    Cancer Res; 2002 Feb; 62(3):625-31. PubMed ID: 11830509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
    Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
    Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
    Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
    Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I
    Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines.
    Buecher B; Bouancheau D; Broquet A; Bezieau S; Denis MG; Bonnet C; Heymann MF; Jarry A; Galmiche JP; Blottière HM
    Anticancer Res; 2005; 25(1A):225-33. PubMed ID: 15816542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A
    Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor.
    Hu KQ; Yu CH; Mineyama Y; McCracken JD; Hillebrand DJ; Hasan M
    Int J Oncol; 2003 Apr; 22(4):757-63. PubMed ID: 12632065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro.
    Mohseni H; Zaslau S; McFadden D; Riggs DR; Jackson BJ; Kandzari S
    J Surg Res; 2004 Jun; 119(2):138-42. PubMed ID: 15145695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual functionality of cyclooxygenase-2 as a regulator of tumor necrosis factor-mediated G1 shortening and nitric oxide-mediated inhibition of vascular smooth muscle cell proliferation.
    Haider A; Lee I; Grabarek J; Darzynkiewicz Z; Ferreri NR
    Circulation; 2003 Aug; 108(8):1015-21. PubMed ID: 12912810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation.
    Steffel J; Hermann M; Greutert H; Gay S; Lüscher TF; Ruschitzka F; Tanner FC
    Circulation; 2005 Apr; 111(13):1685-9. PubMed ID: 15795326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.